MOR208

From HemOnc.org - A Hematology Oncology Wiki
Jump to: navigation, search

Mechanism of action

Anti-CD19 antibody with an engineered Fc region to enhance Fcγ receptor binding affinity

Preliminary data

Chronic lymphocytic leukemia (CLL/SLL)

  1. Woyach JA, Awan F, Flinn IW, Berdeja JG, Wiley E, Mansoor S, Huang Y, Lozanski G, Foster PA, Byrd JC. A phase 1 trial of the Fc-engineered CD19 antibody XmAb5574 (MOR00208) demonstrates safety and preliminary efficacy in relapsed CLL. Blood. 2014 Dec 4;124(24):3553-60. Epub 2014 Oct 9. PubMed

Diffuse large B-cell lymphoma

  1. Abstract: Kami J. Maddocks, Eva González Barca, Wojciech Jurczak, Anna Marina Liberati, Johannes Duell, Zsolt Nagy, Tomáš Papajík, Marc Andre, Nagesh Kalakonda, Martin H. Dreyling, Pier Luigi Zinzani, Sumeet Vijay Ambarkhane, Johannes Weirather, and Gilles A. Salles. L-mind: MOR208 combined with lenalidomide (LEN) in patients with relapsed or refractory diffuse large b-cell lymphoma (R-R DLBCL)—A single-arm phase II study. Journal of Clinical Oncology 2017 35:15_suppl, 7514-7514 link to abstract

Also known as

  • Code names: MOR00208, XmAb5574